Related Experiment Video
Updated: Jun 4, 2026
Tumor Treating Field Therapy in Combination with Bevacizumab for the Treatment of Recurrent Glioblastoma
Published on: October 27, 2014
Brain tumor and Gliadel wafer treatment
M Panigrahi1, P K Das, P M Parikh
1Department of Neurosurgery, Krishna Institute of Medical Sciences, Secunderabad, India.
Abstract:
Glioblastoma is a rapidly progressive and extremely fatal form of brain tumor with poor prognosis. It is the most common type of primary brain tumor. Even with the most aggressive conventional treatment that comprises surgery followed by radiotherapy and chemotherapy, most patients die within a year of diagnosis. Developments in molecular and cell biology have led to better understanding of tumor development, leading to novel treatment strategies including biological therapy and immunotherapy to combat the deadly disease. Targeted drug delivery strategies to circumvent the blood-brain barrier have shown efficiency in clinical trials. Gliadel wafer is a new approach to the treatment of glioblastoma, which involves controlled release delivery of carmustine from biodegradable polymer wafers. It has shown promising results and provides a silver lining for glioblastoma patients.
Insights
Glioblastoma treatment shows promise with Gliadel wafers, a novel approach delivering carmustine directly to the brain tumor. This targeted therapy offers a hopeful advancement for patients facing this aggressive brain cancer.
Area of Science:
- Neuro-oncology
- Biomedical engineering
- Pharmacology
Background:
- Glioblastoma is an aggressive primary brain tumor with a poor prognosis, often fatal within a year despite aggressive conventional treatments like surgery, radiotherapy, and chemotherapy.
- Advances in molecular and cell biology enhance understanding of glioblastoma development, driving novel therapeutic strategies such as biological therapy and immunotherapy.
- Overcoming the blood-brain barrier remains a challenge for effective glioblastoma treatment, necessitating innovative drug delivery systems.
Purpose of the Study:
- To evaluate the efficacy of Gliadel wafers, a novel drug delivery system for glioblastoma treatment.
- To assess the controlled release of carmustine from biodegradable polymer wafers for localized glioblastoma therapy.
- To explore targeted drug delivery strategies as a potential advancement in managing glioblastoma.
Main Methods:
- Utilizing biodegradable polymer wafers for controlled release of carmustine.
- Implementing targeted drug delivery to circumvent the blood-brain barrier.
- Clinical evaluation of Gliadel wafer efficacy in glioblastoma patients.
Main Results:
- Gliadel wafer demonstrated promising results in glioblastoma treatment.
- Controlled release of carmustine from biodegradable wafers showed effectiveness.
- Targeted delivery strategies proved efficient in clinical trials.
Conclusions:
- Gliadel wafer represents a significant advancement in glioblastoma treatment.
- Controlled drug delivery systems offer a hopeful outlook for glioblastoma patients.
- Targeted therapies hold potential for improving outcomes in aggressive brain tumors.
